CAS 495399-09-2

Saroglitazar

Description:

Saroglitazar is a synthetic compound classified as a dual PPAR (peroxisome proliferator-activated receptor) agonist, specifically targeting PPAR-α and PPAR-γ. It is primarily developed for the management of metabolic disorders, particularly type 2 diabetes and dyslipidemia. Saroglitazar exhibits anti-inflammatory and lipid-modulating properties, which contribute to its therapeutic effects. The compound is known to enhance insulin sensitivity and improve lipid profiles by reducing triglyceride levels and increasing HDL cholesterol. Its mechanism of action involves the regulation of genes associated with glucose and lipid metabolism. Saroglitazar is typically administered orally and has been evaluated in clinical trials for its efficacy and safety. As with many pharmaceuticals, potential side effects may include gastrointestinal disturbances, weight gain, or fluid retention, necessitating careful monitoring during treatment. Overall, Saroglitazar represents a promising option in the pharmacological management of metabolic syndrome and related conditions.

Formula: C₂₅H₂₉NO₄S

InChI: InChI=1S/C25H29NO4S/c1-4-29-24(25(27)28)17-19-6-10-21(11-7-19)30-16-15-26-18(2)5-14-23(26)20-8-12-22(31-3)13-9-20/h5-14,24H,4,15-17H2,1-3H3,(H,27,28)/t24-/m0/s1

InChI key: InChIKey=MRWFZSLZNUJVQW-DEOSSOPVSA-N

SMILES: C(COC1=CC=C(C[C@H](OCC)C(O)=O)C=C1)N2C(=CC=C2C)C3=CC=C(SC)C=C3

Synonyms:

• Lipaglyn
• Benzenepropanoic acid, α-ethoxy-4-[2-[2-methyl-5-[4-(methylthio)phenyl]-1H-pyrrol-1-yl]ethoxy]-, (αS)-
• (αS)-α-Ethoxy-4-[2-[2-methyl-5-[4-(methylthio)phenyl]-1H-pyrrol-1-yl]ethoxy]benzenepropanoic acid
• Saroglitazar
• (s)-2-Ethoxy-3-(4-(2-(2-methyl-5-(4-(methylthio)phenyl)-1H-pyrrol-1-yl)ethoxy)phenyl)propanoic acid

Saroglitazar

CAS: 495399-09-2

Saroglitazar

Purity: ≥98%

Molecular weight: 439.57g/mol

Ref: 54-BUP21349

Saroglitazar

CAS: 495399-09-2

Formula: C₂₅H₂₉NO₄S

Molecular weight: 439.57

Ref: 4Z-S-267001

Saroglitazar

Controlled Product

CAS: 495399-09-2

Applications Saroglitazar, is a drug for the treatment of diabetic dyslipidemia and hypertriglyceridemia with Type 2 diabetes mellitus not controlled by statin therapy. Its trade name is Lipaglyn. It is also a 1,2-Diarylpyrroles derivative, which can be used in the preparation of Nonsteroidal anti-inflammatory drugs (NSAIDs).
References Khanna, I. K., et al.: J. Med. Chem., 40, 1619 (1997);

Formula: C₂₅H₂₉NO₄S

Color and Shape: Neat

Molecular weight: 439.57

Ref: TR-S141650

Saroglitazar-d5

Controlled Product

CAS: 495399-09-2

Formula: C₂₅D₅H₂₄NO₄S

Color and Shape: Neat

Molecular weight: 444.598

Ref: TR-S141652

Saroglitazar

CAS: 495399-09-2

Saroglitazar (Lipaglyn) is an agonist of PPAR with EC50 values of 0.65 pM and 3 nM for PPARα and PPARγ.

Formula: C₂₅H₂₉NO₄S

Purity: 98.51%

Color and Shape: Solid

Molecular weight: 439.57

Ref: TM-T12835

Saroglitazar

CAS: 495399-09-2

Saroglitazar is a drug that belongs to the class of peroxisome proliferator-activated receptor (PPAR) agonists. It has been shown to be an effective treatment for type 2 diabetes, and it is used to treat dyslipidemia and metabolic disorders. Saroglitazar has also been shown to have anti-inflammatory effects. Saroglitazar binds to PPAR receptors in the cell membrane, which leads to increased expression of lipoprotein lipase, a key enzyme in lipid metabolism. This effect results in an increase in the uptake of glucose from the blood into cells and improved insulin sensitivity. Saroglitazar has also been shown to activate Toll-like receptor 4 (TLR4), leading to increased expression of interleukin-10 (IL-10) and decreased production of tumor necrosis factor alpha (TNFα). This may be associated with its ability to inhibit HIV replication by downregulating viral transcriptional regulation.

Formula: C₂₅H₂₄H₅NO₄S

Purity: Min. 95%

Molecular weight: 444.6 g/mol

Ref: 3D-VUA39909